Synta Pharmaceuticals Corp. (NASDAQ:SNTA)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that address severe medical conditions with potential markets, including cancer and chronic inflammatory diseases.

Recs

0
Player Avatar nguyenvanh (< 20) Submitted: 6/29/2007 5:24:15 PM : Outperform Start Price: $8.36 SNTA Score: -41.45

Strong cash. Insider purchases.

Featured Broker Partners


Advertisement